Skip to content

Study · Randomized controlled trial · n = 186 · 2026

4 results

Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease.

Node K, Batterham RL, Liu-Seifert H, Li R, Yoshino M, Oura T, Tanizawa Y, Komuro I

Current medical research and opinion1 Apr 2026

PMID42287159 (opens in a new tab)DOI10.1080/03007995.2026.2686052 (opens in a new tab)PepBankPUB-42287159
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, the reduction in predicted CVD risk with tirzepatide was evident by Week 8 and sustained through Week 72.

    In plain wordsIn Japanese adults with obesity, the drop in predicted heart disease risk with tirzepatide showed by week 8 and lasted to week 72.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTime course of predicted CVD risk reduction
    Study

    n = 186

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 mg or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Reduction in predicted risk was evident by Week 8 and sustained through Week 72.
    1 context sentence
    Summary · context
    Adults meeting the JASSO criteria for obesity disease and without prior CVD received once-weekly tirzepatide (10 mg or 15 mg) or placebo for 72 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, tirzepatide 10 mg reduced predicted 10-year CVD risk by 2.8% at Week 72, while placebo increased it by 2.0%.

    In plain wordsIn Japanese adults with obesity, tirzepatide 10 mg lowered the predicted 10-year heart disease risk, while the risk rose with placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreasePredicted 10-year CVD risk change at Week 72, tirzepatide 10 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 mg · 72 weeksAs given in this study (human).

    Measurements

    Mean absolute change in predicted 10-year CVD risk
    −2.8%
    10 mg
    Hazard ratio
    0.65 ratio
    10 mg vs placebo

    Source sentences

    Summary
    Tirzepatide treatment was associated with significant reductions in predicted 10-year CVD risk at Week 72, with mean absolute reductions from baseline of 2.8% (95% confidence interval [CI]: -3.7%, -1.9%) (10 mg) and 2.5% (95% CI: -3.4%, -1.6%) (15 mg) versus an increase of 2.0% (95% CI: 1.1%, 2.9%)…
    1 context sentence
    Summary · context
    Adults meeting the JASSO criteria for obesity disease and without prior CVD received once-weekly tirzepatide (10 mg or 15 mg) or placebo for 72 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity disease, tirzepatide 15 mg reduced predicted 10-year CVD risk by 2.5% at Week 72, while placebo increased it by 2.0%.

    In plain wordsIn Japanese adults with obesity, tirzepatide 15 mg lowered the predicted 10-year heart disease risk, while the risk rose with placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreasePredicted 10-year CVD risk change at Week 72, tirzepatide 15 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    15 mg · 72 weeksAs given in this study (human).

    Measurements

    Mean absolute change in predicted 10-year CVD risk
    −2.5%
    15 mg
    Hazard ratio
    0.68 ratio
    15 mg vs placebo

    Source sentences

    Summary
    Tirzepatide treatment was associated with significant reductions in predicted 10-year CVD risk at Week 72, with mean absolute reductions from baseline of 2.8% (95% confidence interval [CI]: -3.7%, -1.9%) (10 mg) and 2.5% (95% CI: -3.4%, -1.6%) (15 mg) versus an increase of 2.0% (95% CI: 1.1%, 2.9%)…
    1 context sentence
    Summary · context
    Adults meeting the JASSO criteria for obesity disease and without prior CVD received once-weekly tirzepatide (10 mg or 15 mg) or placebo for 72 weeks.
  4. 04Computer modelIn silicoEfficacy outcome

    In a model extrapolated to about 5.1 million treatment-eligible adults in Japan, tirzepatide 10 mg was projected to prevent 123,000 CVD events over 10 years, versus an estimated increase of 88,000 events with placebo.

    In plain wordsA model for Japan projected 123,000 fewer heart disease events over 10 years with tirzepatide 10 mg, versus 88,000 more with placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProjected preventable CVD events over 10 years, tirzepatide 10 mg
    Study

    n: not reported in source

    Model-based extrapolation to treatment-eligible adults in Japan
    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 mg · 10 yearsAs given in this study.

    Source sentences

    Summary
    Extrapolated to approximately 5.1 million estimated treatment-eligible individuals in Japan without prior CVD, the projected model-based estimate for number of potentially preventable CVD events with tirzepatide treatment (10 mg) is 123,000 CVD events over 10 years, compared with an estimated increa…
    1 context sentence
    Summary · context
    Adults meeting the JASSO criteria for obesity disease and without prior CVD received once-weekly tirzepatide (10 mg or 15 mg) or placebo for 72 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04844918

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

Eli Lilly and Companyn = 26710 May 2021 to 24 Jun 2023

Obesity

Trial pageClinicalTrials.govUpdated 16 Jul 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.